In an article from 340B Report which states that AbbVie will expand its contract pharmacy restrictions with new claims data reporting requirements for 340B grantee covered entities beginning Jan.1. ACH’s Stephanie Krenrich, senior vice president of policy & government affairs, said ACH recognizes the need for compliance with the 340B statute and is advocating for […]
A learning collaborative is an initiative in which teams of peers come together to study and apply quality improvement methodology to a focused topic area. First conceived by the Institute for Healthcare Improvement (IHI) in 1994, learning collaboratives help organizations apply known improvement principles to current health care practices with the goal of achieving “breakthrough […]
Dear ACH Members, I know many might be questioning what this election means for health centers, wondering if the outcome changes the focus of our work towards securing health center funding, realizing 340B reform, advocating for workforce needs, ensuring financial sustainability for health centers, and more. ACH has prepared for this outcome and stands ready to fight […]
The 340B Drug Pricing Program is a game changer for federally qualified health centers (FQHCs), which have limited flexible funding streams at their disposal and often use their 340B savings for services that are non-reimbursable. The financial impact of these savings cannot be overstated, as they allow FQHCs to stretch their already scarce federal resources […]
ACH’s statement was included in Inside Health Policy’s article today on HRSA’s letter to J&J on their proposed 340 drug rebate program: “The drug company notified its customers of the shift last month and insists the policy is fully compliant with statutory requirements and may help ensure safety net hospitals are better able to meet the […]
ACH’s statement was included in Bloomberg Law’s article today on HRSA’s letter to J&J on their proposed 340 drug rebate program: HRSA wrote it expects J&J to cease implementation immediately and to inform the agency no later than Sept. 30 in order to provide adequate notice to covered entities. Hospital groups including 340B Health and Advocates […]
Advocates for Community Health (ACH) applauds the Health Resources and Services Administration (HRSA)’s strong and clear statement today that a rebate model is not consistent with the 340B Drug Discount Pricing Program, and that they will take enforcement action against companies that pursue one. The rebate model is especially challenging for community health centers, and we are […]
U.S. Senator Peter Welch (D-Vt.) yesterday introduced the bicameral 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support (PATIENTS) Act, legislation that would protect the 340B drug pricing program and ensure patients—especially those in lower income and rural communities—can continue care with providers who utilize the program. ACH provided the following statement in support […]
“One group desperately hoping Congress acts is community health centers, who were some of the original intended beneficiaries of 340B,” writes Michael McAuliff at Modern Healthcare. “Advocates had hoped to see a final draft of the SUSTAIN Act ahead of National Health Center Week in Washington this week. ‘The program has begun to narrow over […]
Advocates for Community Health (ACH) is tirelessly advocating and urging federal policymakers to ensure that America’s largest network of primary care providers can continue caring for more than 31 million patients annually in underserved communities. This will require proper funding and resources to position community health centers (CHCs) at the core of the healthcare system. […]